SCHEMBL7184527

SCHEMBL7184527

Cc1cc(C)c(C(=O)P(=O)(C(=O)c2c(Cl)ccc(Cl)c2Cl)c2ccccc2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
LMNA P02545 4/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
TP53 P04637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
APAF1 O14727 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
MCL1 Q07820 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
S1PR4 O95977 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181255 0.93 MEN1 (0.37) MEN1KMT2ARAB9ANPC1TAS1R3
SCHEMBL7174830 0.90 MEN1 (0.39) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL7181097 0.89 KMT2A (0.42) MEN1KMT2ARAB9AMAPTTP53
SCHEMBL7184115 0.89 TYK2 (0.39) KMT2ANPC1MAPTALDH1A1L3MBTL1
SCHEMBL7182320 0.88 RAB9A (0.36) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL7186634 0.87 KMT2A (0.37) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL15158 0.87 LMNA (0.40) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL7177492 0.87 NPC1 (0.33) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL7182411 0.86 KMT2A (0.40) MEN1KMT2ARAB9ALMNAMAPT
SCHEMBL25250816 0.85 LMNA (0.39) MEN1KMT2ARAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885KMT2A 1586/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885KMT2A 956/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.